Extended Data Fig. 7. Anti-IL11 therapy improves muscle strength and metabolic health in old male mice.
a-k Data for anti-IL11 therapeutic dosing experiment as shown in Schematic Fig. 3a in which IgG or X203 were administered to male mice starting from the age of 75 weeks. a Forepaw grip strength, b RER measurements, cumulative food intake, and locomotive activities as measured by phenomaster for 5 days on IgG/X203-treated old (81-week-old) male mice − 6 weeks after IgG/X203 administration was started (n = 10/group). c Faecal caloric density as measured by bomb calorimetry in IgG and X203-treated 115-week-old male mice (IgG, n = 8; X203, n = 10). Serum levels of d cholesterol, TG, e IL6, and f AST, indexed weight of g soleus, h scWAT and BAT, and i WB of total proteins for the respective phospho-proteins in vWAT shown in Fig. 3m (n = 6/group). j telomere length and k mtDNA copy number. a, c-h, j-k Data are shown as mean ± SD. a, d-h, j-k One-way ANOVA with Tukey’s correction (75-week-old control, n = 6 (h), n = 10 (a), n = 14 (d-g, j-k); untreated 100-week-old, n = 6; IgG 100-week-old, n = 13; X203 100-week-old, n = 12); c two-tailed Mann Whitney test; j two-tailed Student’s t-test. For gel source data, see Supplementary Fig. 1. BW: body weight; FC: fold change.